Neurological Disorders

Wednesday, February 12, 2025

Neurological Disorders

Raising Awareness of Hidden Disabilities – The Struggles of Families with Life-Limiting Conditions

Raising Awareness of Hidden Disabilities – The Struggles of Families with Life-Limiting Conditions

Hidden disabilities, often overlooked by the public, can profoundly impact daily life, even when their effects are not immediately visible. Conditions like chronic pain, neurological disorders, and autoimmune diseases can challenge individuals without being recognized at first glance, as highlighted by Hidden Disabilities UK.

For Emma and her daughter Izzy, this reality is all too familiar. Izzy, a curious and energetic child with a life-threatening condition, appears no different from any other child. She enjoys participating in school shows, reading books, writing stories, and playing with her friends. However, because her condition is not outwardly visible, Emma and her husband Neil often face scepticism when using disabled parking spaces, with strangers unaware of Izzy’s hidden struggles.

“People assume everything is fine because Izzy doesn’t ‘look sick,’ but they don’t see the sleepless nights, medical equipment, or constant worry,” says Emma. “Yes, this is finIt’s wonderful in many ways that no one knows Izzy was so sick when she was little, and even now, while she is stable, they have no idea about the extra care. But that also makes it exhausting as people wonder why you feel so anxious and worried much of the time!”

This scenario ties into broader issues discussed by disability advocacy groups, such as The Disability Rights Commission (UK), which address the misuse of blue badges and, alongside this, the challenges by members of the public to disabled people who don’t look disabled.* The frequent misunderstandings faced by families like Izzy’s highlight the ongoing struggle for recognition of hidden disabilities.

In addition, families facing life-threatening conditions, like Izzy’s, often endure emotional strain and isolation, highlighting the urgent need for greater support and awareness. Charities such as Jessie May, the South West’s children’s hospice at home, play a vital role by providing expert medical care, emotional support, and respite, allowing families to focus on spending quality time together despite the challenges.

“Jessie May has made such a difference for us,” Emma says. “Their support allows us to feel more like a family and less like we’re just managing a condition.”

“Life-limiting conditions are not always visible, but the challenges are very real,” says Jessie May nurse Steve. “I have seen Izzy grow up and witnessed both her resilience and the immense effort her family puts into her care. Behind her smiles and laughter, there’s a level of vigilance and dedication that many wouldn’t realise.”

This year, Jessie May is urging the public to acknowledge the hidden battles families like Emma’s face and to contribute to making their journey a little easier. At a time for giving, small acts of kindness can make a big difference, bringing comfort and connection to families facing hidden disabilities, whether through donations, volunteering, or raising awareness.

BioArctic Doses First Patient in Phase 2a Study of Exidavnemab for Parkinson’s Disease

BioArctic Doses First Patient in Phase 2a Study of Exidavnemab for Parkinson’s Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the successful dosing of the first patient in the EXIST Phase 2a study evaluating exidavnemab for Parkinson’s disease. Exidavnemab, a monoclonal antibody, specifically targets aggregated forms of the protein α-synuclein, which is believed to contribute to the progression of Parkinson’s and other neurological disorders.

The Phase 2a trial, titled EXIST (EXIdavnemab Synucleinopathy Trial), is a randomized, double-blind, placebo-controlled study designed to assess the safety and tolerability of exidavnemab in Parkinson’s patients. Conducted in Europe, the trial will enroll at least 24 participants, divided into two cohorts of 12 patients each.

  • Cohort 1: Receives either a lower dose of exidavnemab or placebo.
  • Cohort 2: Receives either a higher dose of exidavnemab or placebo.

In addition to safety and tolerability as primary endpoints, researchers will assess a comprehensive set of biomarkers through plasma, cerebrospinal fluid (CSF) samples, and advanced digital measurements to gather detailed insights.

“We are very excited that the first patient with Parkinson’s disease has now been dosed in the EXIST Phase 2a study with exidavnemab,” said Gunilla Osswald, CEO at BioArctic. “It marks an important next step on BioArctic’s pioneering journey to broaden our research portfolio and help more patients and families with different neurological disorders to a better life.”

Recently, the results of two separate Phase 1 studies of exidavnemab, conducted in collaboration with AbbVie, were published in The Journal of Clinical Pharmacology. The results showed that exidavnemab is generally well-tolerated, with an excellent half-life of approximately 30 days. These data together with the high affinity and selectivity toward the pathological aggregated forms of α-synuclein, key to maintaining a high target binding in the brain, laid the foundation for the Phase 2a study.